Latest News and Press Releases

Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with...

Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity...

Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma...

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Press Release – No. 2 / 2025 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity Copenhagen, Denmark, January 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)...

Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th Copenhagen, Denmark, January 6, 2025 – Zealand Pharma A/S (CVR-no....

Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...

Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA...

Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the...